Literature DB >> 8751249

The risk of stroke in the early postoperative period following mitral valve replacement.

T A Orszulak1, H V Schaff, J R Pluth, G K Danielson, F J Puga, D M Ilstrup, B J Anderson.   

Abstract

All patients (285) undergoing mitral valve replacement (MVR) with a Carpentier-Edwards (C-E) bioprosthesis +/- coronary bypass grafts (CABG) were reviewed (109 men and 176 women with a median age of 70 years). Overall, the 5-year survival rate was 58.9%, 62.7% for MVR (199 patients) and 50.1% for MVR+CABG (86 patients). Late survival was adversely affected by the operative time variables of NYHA class IV, older (> or = 70 years) age, low (> or = 56%) ejection fraction (EF), and the additional performance of associated procedures+CABG with MVR (P < or = 0.001). The 5-year freedom from stroke rate was 89.2%, 89.1% for MVR and 90.2% for MVR +/- CABG. Advanced heart class was the only significant variable associated with a greater risk of late stroke (P < or = 0.01). Neither chronic preoperative atrial fibrillation nor operative obliteration of the left atrial appendage increased or decreased the late risk of stroke in patients following MVR. Hazard function for stroke occurring in the first postoperative year (first 48 h excluded to discount intraoperative events) demonstrated the highest rate within the first month (40%), rapidly diminishing thereafter. This pattern was reproduced in the 12-year hazard function in that the rate of stroke occurrence was greatest in the first year (6.7%) following implantation. The mean stroke rate over 12 years was 2.5%. Strokes following MVR +/- CABG are more likely to occur in older and more compromised patients, and the higher early rate is not reflected in the mean rate. A more aggressive approach to early anticoagulation with IV heparin, Coumadin, and possibly antiplatelet therapy is advocated to reduce this complication rate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8751249     DOI: 10.1016/s1010-7940(05)80106-x

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Richard P Whitlock; Jack C Sun; Stephen E Fremes; Fraser D Rubens; Kevin H Teoh
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Surgery for atrial fibrillation.

Authors:  Richard Lee; Jane Kruse; Patrick M McCarthy
Journal:  Nat Rev Cardiol       Date:  2009-08       Impact factor: 32.419

Review 3.  Interventional and surgical occlusion of the left atrial appendage.

Authors:  Etem Caliskan; James L Cox; David R Holmes; Bernhard Meier; Dhanunjaya R Lakkireddy; Volkmar Falk; Sacha P Salzberg; Maximilian Y Emmert
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

Review 4.  Antithrombotic strategy in the three first months following bioprosthetic heart valve implantation.

Authors:  André R Durães; Milena A O Durães; Luis C L Correia; Roque Aras
Journal:  Arq Bras Cardiol       Date:  2013-10-08       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.